Shares of Advaxis Inc. dropped more than 13 percent in pre-market activity before paring losses to just more than 5 percent after the company said that it was not able to complete the second stage of the Phase 2 GOG-0265 trial as designed due to a clinical hold that affected its clinical development programs last year.
from RTT - Biotech http://ift.tt/2f0ilOp
via IFTTT
No comments:
Post a Comment